Analyst Reco. Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:32:17 21/01/2026 pm IST			5-day change	1st Jan Change
216.34 ^USD	-0.86%		-0.88%	+4.68%

09:57pm	Top Midday Stories: Trump Says US Doesn't Want to Use Force to Acquire Greenland; Netflix Shares Fall on Low Q1 Guidance	MT
09:55pm	Wall Street regains momentum as Trump speaks at Davos

Analyst Reco.

09/01	Bernstein Adjusts PT on Johnson & Johnson to $208 From $193, Maintains Market Perform Rating	MT
07/01	Stifel Adjusts Price Target on Johnson & Johnson to $205 From $190, Maintains Hold Rating	MT
05/01	Wolfe Research Adjusts PT on Johnson & Johnson to $240 From $225, Maintains Outperform Rating	MT
30/12	Barclays Adjusts PT on Johnson & Johnson to $217 From $197, Maintains Equalweight Rating	MT
18/12	Goldman Sachs Adjusts Johnson & Johnson Price Target to $240 From $213, Maintains Buy Rating	MT
17/12	RBC Lifts Price Target on Johnson & Johnson to $240 From $230, Maintains Outperform Rating	MT
15/12	Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says	MT
12/12	Wells Fargo Adjusts Price Target on Johnson & Johnson to $230 From $212, Maintains Overweight Rating	MT
12/12	Morgan Stanley Adjusts PT on Johnson & Johnson to $197 From $190, Maintains Equalweight Rating	MT
11/12	Johnson & Johnson Positioned for Growth on Multiple MedTech and Immunology Catalysts, RBC Says	MT
11/12	RBC Raises Price Target on Johnson & Johnson to $230 From $209, Keeps Outperform Rating	MT
11/12	Citigroup Adjusts Price Target on Johnson & Johnson to $232 From $215, Maintains Buy Rating	MT
10/12	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
10/12	HSBC Adjusts Price Target on Johnson & Johnson to $240 From $215, Maintains Buy Rating	MT
05/12	Guggenheim Adjusts Price Target on Johnson & Johnson to $227 From $206, Maintains Buy Rating	MT
01/12	Barclays Adjusts Price Target on Johnson & Johnson to $197 From $176, Maintains Equalweight Rating	MT
18/11	Sector Update: Health Care Stocks Softer Late Afternoon	MT
13/11	Scotiabank Initiates Johnson & Johnson at Sector Outperform With $230 Price Target	MT
07/11	America's markets lose their nerve
07/11	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
06/11	J&J says FDA approves Caplyta as add-on depression treatment	RE
05/11	Recursion Pharmaceuticals, Inc. Announces Management Changes, Effective January 1, 2026	CI
27/25/27	Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	MT
27/25/27	Johnson & Johnson's Study Shows Clinically Meaningful Results for Icotrokinra in Ulcerative Colitis Patients	MT
27/25/27	Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

October 14, 2025 at 09:50 pm IST

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 07:23 pm IST